-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 9, Novaliq announced that it has submitted a New Drug Application (NDA) to the FDA for CyclASol® (0.
SHR8028 eye drops is an anti-inflammatory and immunomodulatory agent, oil-free, surfactant-free, paraben-free, with high topical bioavailability, reduction of blurred vision caused by oil-based eye drops, and improved ocular surface comfort degree advantage
In November 2019, Hengrui reached an agreement from Novaliq GmbH in Germany to introduce the exclusive rights for the clinical development, production and marketing of dry eye drugs CyclASol and NOV03 (perfluorohexyloctane) in China, with a total sales of up to 165 million dollars
In December 2021, Novaliq announced positive results from a pivotal Phase III clinical trial (ESSENCE-2) of CyclASol in dry eye disease
Dry eye syndrome, also known as keratoconjunctiva xerophthalmia, is a general term for a group of diseases that cause dryness of the ocular surface epithelium due to low tear secretion or other causes of abnormal tear film.